Psychedelics
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment […]
MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 […]
Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread […]
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia–(November 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on […]
Revitalist Opens Seventh Clinic Increasing Revenue Capacity to $51.55 Million USD
November 24, 2021 08:30 AM Eastern Standard Time VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to formally announce the opening of its seventh psychedelic assisted psychotherapy (“PAP”) clinic located at 42450 Twelve Mile Road, Novi, Michigan, 48377. “Revitalist is providing Novi access to much […]
TORONTO–(BUSINESS WIRE)-11/23/2021- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. The […]
Clearmind Medicine to Pursue Dual Listing on Nasdaq
Toronto, Ontario, Nov. 22, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that its board of directors has decided to pursue a dual listing […]
Revitalist Acquires Revitaland Meta Tech to Expand Virtual Clinics in the Metaverse
VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce it has acquired a 60% interest in Revitaland Meta Tech Inc. to expand virtual clinics in the metaverse (“Revitaland”). The development of Revitaland will be carried out by Metachain Technologies Inc. (“META”), a company experienced […]
Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form
TORONTO, November 18, 2021–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND) (FSE: 3XI), a leading biotech company in fast-acting psychedelics, announces today the Company’s completion of the development of a novel thermosensitive nasal gel delivery system for its N, N-dimethyltryptamine (“DMT”) and 5-MeO-DMT product candidates. The product candidates are aimed at treating depression, […]
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics VANCOUVER, BC, Nov. 18, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing procedure as […]
Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project Toronto, Ontario–(Newsfile Corp. – November 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces it has […]
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease
The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing procedure for […]
Allied Corp Progresses Towards Clinical Phase I Trial for Psilonex™ RX Psilocybin Pharma Drug
KELOWNA, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID) is pleased to announce the advancement of the Psilonex™ RX human clinical phase I trial. Allied has now sourced the active pharmaceutical ingredients contained in Psilonex™ and is now moving towards producing the Psilonex™ to be used at one of […]
With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III Toronto, Ontario (November 16, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has […]
November 16, 2021 08:31 AM Eastern Standard Time VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce its clinic operations generated approximately $1.55 million in revenue for the ten months ended October 31, 2021, compared to $789,000 for the same period in […]
Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights
FDA Authorization of Historic Phase I Clinical Trial Using All-Natural Psychedelic Compounds and Direct Psilocin Administration for the First Time Granted First and Only Patent for Extraction and Standardization of Natural Psilocybin Health Canada Dealer’s License Enables Production and Distribution of All Natural cGMP-Grade Psychedelic Supply from its Facilities VANCOUVER, BC, Nov. […]
Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets
Vancouver, British Columbia–(Newsfile Corp. – November 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that its common stock ticker will change from “GTSIF” to “LOBEF” and will commence trading under the symbol “LOBEF” in US markets at the opening of the market on November 15, 2021 […]
The proposed collaboration is expected to: Assess the compatibility of the RYAH Smart Patch delivery and monitoring device, software, and data platform with Ei.Ventures’ proprietary psychedelic formulations Further Ei.Ventures’ research and development strategy, accelerating use testing on controlled delivery and monitoring of psychoactive compounds for mental wellness treatments Position the companies toward a commercial licensing […]
Silo Pharma Reports Third Quarter Results and Operating Highlights
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business. Operating Highlights Entered sponsored research agreement with Columbia […]
Nutritional High Renames Psychedelic Subsidiary and Appoints Ian Campbell as CEO
Toronto, Ontario–(Newsfile Corp. – November 10, 2021) – Nutritional High International Inc. (CSE: EAT) (“Nutritional High” or the “Company“) is pleased to announce the name change of its wholly-owned subsidiary Psychedelic Science Corp., which it acquired in August 2020 (please see the press releases dated August 17, 2020 and February 10, 2021) and appointment of Ian Campbell as […]
Revitalist CEO Kathryn Walker Receives Entrepreneur of the Year Award at Wonderland, Miami
VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE:4DO) is pleased to announce that Revitalist CEO Kathryn Walker has received Microdose’s “Entrepreneur of the Year” award at Wonderland: Miami, the largest psychedelic medicine business event. Kathryn founded Revitalist with one clinic in Knoxville, Tennessee in early 2018. […]
Revitalist Executes LOI to Enter into a Clinical Research Collaboration with MYND
VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce it has executed a binding letter of intent (“LOI”) with MYND DIAGNOSTICS INC., (“MYND Diagnostics”), a wholly owned subsidiary of MYND LIFE SCIENCES INC. (“MYND”) (CSE:MYND) (OTC:MYNDF) to enter into a clinical research collaboration studying a link between diagnostic […]
World’s first systematic, pharmacokinetic/pharmacodynamic study of non-psychedelic doses of psilocybin TORONTO, Nov. 8, 2021 /CNW/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on non-hallucinogenic, psychedelic-based therapies for use in the treatment of mental health, today announced the dosing of the first cohort of its Phase 1 clinical trial. This is the […]
Revitalist Brings Together Impressive Team to Improve Mental Health
Mental health disorders account for several of the top causes of disability in the U.S. and worldwide. In fact, 26% of Americans ages 18 and older—or about one in four adults—have a diagnosable mental disorder in a given year. In addition, nearly 10% of American adults will also suffer from a depressive illness, such as […]
PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye Diseases
PharmaDrug narrows list of candidate tryptamine molecules for the treatment of primary open angle glaucoma (PAOG) Terasaki Institute receives PharmaDrug’s two candidate DMT analogue molecules Terasaki Institute, initiates supportive IND-enabling mechanism of action studies to evaluate potency and kinetics of PharmaDrug’s DMT analogues Toronto, Ontario–(Newsfile Corp. – November 5, 2021) – PharmaDrug Inc. (CSE: […]
Ehave, Inc. To Sponsor Major Psychedelics Conference, Wonderland: Miami
Wonderland: Miami is hosted by Microdose and engages some of the greatest minds in the Psychedelic Sector, by fostering creative and professional growth Miami, Florida–(Newsfile Corp. – November 5, 2021) – Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it will […]
Cybin Granted DEA Schedule I Manufacturing License
November 04, 2021 07:00 AM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the Company has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for […]
Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet, despite significant investment in clinical trials, the FDA has only approved two types of […]
Pharmala Biotech Announces Hiring of Harpreet Kaur as Vice President of Research
Dr. Kaur to accelerate PharmAla’s pre-IND program Toronto, Canada – PharmAla Biotech today announced the hiring of Dr. Harpreet Kaur as its new Vice President of Research, responsible for completion of the Company’s Pre-IND research into its novel formulations of MDMA. PharmAla has developed a novel formulation of MDMA, with a focus on reducing the […]
Revitalist Launches Division Dedicated to Assist Law Enforcement
VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE:4DO) is proud to announce it has contracted with Enterprise Stress Management (“ESM”) to develop and commercialize mental health therapies, techniques, and advocacies for police officers across Canada. “We are thrilled to work with Katherine Plewa and the ESM team […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its CBD/THC cannabis formulations including ARLO CBD Beauty and InVibe® MD (“health & wellness” line), and secondly, its unique DermSafe® hand sanitizer; all made with its patented Invisicare® skin delivery technology.
The Green Organic Dutchman Holdings Ltd. is a premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe and Latin America and the Canadian adult-use market. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
